Chemotherapies of varying classes often cause neuropathy and debilitating chemotherapy-
induced neuropathic pain sufficient to limit treatment and reduce quality of life for many …

Patients treated with cancer chemotherapeutics frequently report chemotherapy-induced
peripheral neuropathy (CIPN), changes in mood (depression and anxiety) and functional …

Chemotherapy-induced neuropathic pain (CINP) remains a therapeutic challenge, with no
US-FDA approved drugs or effective treatments available. Despite significant progress in …

Paclitaxel is a cancer chemotherapy drug with adverse effects that include chemotherapy-
induced neuropathic pain (CINP) as well as depression of behavior and mood. In the clinical …

Chemotherapy-induced peripheral neuropathy (CIPN) is the major dose-limiting side-effect
of many front-line anticancer drugs. This study was designed to establish and …

BACKGROUND: Painful neuropathy is a dose-limiting side effect in cancer chemotherapy.
To characterize this phenomenon, we examined pain behavior and analgesic actions in a …

Chemotherapy-induced neuropathic pain is one of the major problems for cancer patients.
Although paclitaxel and cisplatin are widely used in women, most laboratory studies of …

This review examines recent preclinical research on toxic peripheral neuropathy and
potential therapeutic developments. Chemotherapy-induced peripheral neurotoxicity is a …

Chemotherapy-induced peripheral neuropathy is a common, dose-limiting side effect of
cancer chemotherapeutic agents, including the vinca alkaloids such as vincristine. The …

Painful peripheral neuropathies resulting from cancer chemotherapy treatment is frequently
dose-dependent and may diminish following dose reduction or termination of chemotherapy …